Six questions decide this, and none of them is which peptide. What condition is being treated and how was it established. Is there an approved product for it. What happens to fertility. What gets monitored and how often. What is the plan for stopping. And does this end a man’s eligibility in tested sport. A service that answers all six is practicing medicine rather than selling merchandise.
What is being treated, and what established it
Men arrive at this market with symptoms, not diagnoses: flat energy, weaker sessions in the gym, lower drive, slower recovery, a thicker midsection. Those symptoms overlap heavily with conditions that have nothing to do with peptide availability. Obesity suppresses measured testosterone through recognized mechanisms and reverses when weight comes down. Obstructive sleep apnea is associated with lower total testosterone. A single week of restricted sleep lowered daytime testosterone in young healthy men. Erectile dysfunction is associated with cardiometabolic risk closely enough to be worth working up rather than papering over.
Symptom questionnaires do not close that gap. Validation work on one widely used aging-male questionnaire found it performed poorly as a screening instrument for hypogonadism. Professional guidance asks for consistent symptoms plus low morning fasting total testosterone confirmed on two separate occasions before anyone starts treatment. One convenient draw at four in the afternoon does not meet that bar.
Is there an approved product for this condition
If the answer is yes, that is where the conversation should start. Testosterone products are approved for men with hypogonadism tied to an identified medical condition. Tesamorelin is approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy and its label notes the drug is weight neutral. Semaglutide and tirzepatide carry weight and cardiometabolic indications, and tirzepatide also covers moderate to severe obstructive sleep apnea in adults with obesity. Bremelanotide is approved, but for premenopausal women with hypoactive sexual desire disorder, and its label states it is not indicated in men.
If the answer is no, the honest framing is that an unapproved compound is being tried for a condition with no approved treatment, and everyone in the room should say so.
Where an approved product exists, it is often available through named channels that make the indication explicit. LillyDirect ties orders to a manufacturer’s labeling, Ro and Hims and Hers publish who qualifies for what, and a provider such as HealthRX lists the conditions its peptide therapy is meant to address. Starting from a provider that names the indication keeps the first of these six questions in plain view.
What happens to fertility
This is the question most men do not think to ask, and it is the one with the clearest answer. Exogenous testosterone suppresses the pituitary signals that drive sperm production. A review of non-medical androgen use in young men catalogs the fertility consequences alongside the psychological and cardiovascular ones. Any man who may want children should have that conversation before the first prescription, not after a semen analysis comes back empty, and alternatives that preserve the hypothalamic-pituitary axis exist for some presentations.
What gets monitored, and what a good answer sounds like
| Question | A usable answer | An answer that should stop the process |
|---|---|---|
| What labs before starting? | Two morning fasting total testosterone draws, plus hematocrit and a workup for the causes that mimic this | A questionnaire score, or a single draw taken at any hour |
| What gets rechecked, and when? | Testosterone, hematocrit and prostate-relevant assessment on a stated schedule | Nothing scheduled, or labs only if the patient asks |
| Who reads the results? | A named clinician licensed in the patient’s state | An automated dashboard, or nobody identified |
| Which pharmacy fills it? | A named pharmacy, checkable on a state board register | Refusal to name it, or a vendor with no pharmacy at all |
| Is this compound FDA-approved? | A direct yes or no, with the indication read out | Clinically proven, pharmaceutical grade, or research backed |
| What is the exit plan? | A stated approach to stopping and to what happens afterward | An indefinite subscription with no review point |
Hematocrit deserves specific mention because it is the monitoring item most often dropped. Secondary erythrocytosis has been documented across testosterone formulations in matched-cohort analysis, and it is found by a routine blood count that costs very little. A plan that never rechecks it is cheaper for exactly one reason.
What does the whole year cost, and who is answerable
Ask for the twelve-month figure with every recurring charge counted: medication, membership, consultations, laboratory panels, shipping and supplies. Then ask who picks up the phone when something goes wrong. Direct-to-consumer platforms such as Hims and Ro, men’s clinic networks such as Marek Health and Defy Medical, and physician-supervised compounding services including FormBlends structure oversight and billing differently, so two quotes that look similar each month can differ once monitoring is included.
What is the plan for stopping
Every option here has an exit question and most sales pages avoid it. Testosterone suppresses the body’s own production while it is being taken, so stopping is a clinical event that needs a plan. For the unapproved compounds the exit question is different and simpler: there is no evidence that they were doing anything, so the honest review point is whether the stated goal moved at all.
Does this end eligibility in tested sport
For a man competing in anything tested, including masters events and many collegiate programs, this is decisive. Testosterone falls under section S1 of the World Anti-Doping Code prohibited list and growth hormone secretagogues fall under section S2. Analytical methods for detecting growth hormone releasing peptides in urine and blood are published and in routine use. A prescription does not create an exemption on its own.
Frequently asked questions
Should a man with normal testosterone consider these compounds anyway?
Testosterone products are not approved for men with normal levels, and the growth hormone pathway that the unapproved peptides target has been tested directly in healthy adults. Lean mass shifted slightly while strength and exercise capacity did not. There is no result there worth the exposure.
How many blood draws should a diagnosis take?
Professional guidance asks for at least two morning fasting total testosterone measurements on separate days, because levels fluctuate daily and drop with acute illness, poor sleep and recent weight gain. One low reading is a reason to repeat the test, not a reason to start a prescription.
Is fertility loss from testosterone permanent?
Suppression of sperm production is expected during treatment and recovery after stopping varies between men and can take many months. Duration of use and baseline fertility both matter. A man who wants children should raise this before starting so alternatives and sperm banking can be discussed while the options are still open.
What if a service will not answer one of these questions?
Treat the non-answer as the answer. Every one of these is routine for a clinician who ordered the labs and knows which pharmacy fills the prescription. Vagueness about diagnosis, monitoring, the pharmacy or the exit plan describes a sales process, not a treatment plan.
